Objective:
To discuss progression predictors, emerging therapies, and the role of AI in geographic atrophy (GA) care.
Approach:
- Current and Emerging Treatments: Reviewed current treatments like pegcetacoplan and avacincaptad pegol, and discussed emerging therapies including oral therapies, mitochondrial stabilization, gene therapy, and retinal implants.
Key Findings:
- OCT can reveal warning signs of GA years before significant vision loss occurs.
- High-risk OCT features include hyper-reflective foci, large drusen volume, and outer retinal disruption.
- Current treatments can slow GA progression but do not restore vision.
- AI may help predict individual patient risk of progression and inform treatment strategies.
Interpretation:
The integration of advanced imaging and AI in GA care allows for earlier intervention and more personalized treatment approaches.
Limitations:
- The study does not provide specific data on the effectiveness of emerging therapies.
- Longitudinal data on AI predictions and their clinical application is still developing.
Conclusion:
GA care is evolving with a focus on early detection and innovative therapies.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.